BRIEF-Solid Biosciences Gets FDA IND, Health Canada CTA Nod for First-In-Class Cardiac Gene Therapy CPVT
Reuters
Jul 09, 2025
BRIEF-<a href="https://laohu8.com/S/SLDB">Solid Biosciences</a> Gets FDA IND, Health Canada CTA Nod for First-In-Class Cardiac Gene Therapy CPVT
July 8 (Reuters) - Solid Biosciences Inc SLDB.O:
SOLID BIOSCIENCES ANNOUNCES FDA IND AND HEALTH CANADA CTA APPROVAL FOR FIRST-IN-CLASS CARDIAC GENE THERAPY TO TREAT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)
SOLID BIOSCIENCES INC - EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN Q4 OF 2025
SOLID BIOSCIENCES INC - PHASE 1B CLINICAL TRIAL FOR SGT-501 EXPECTED IN Q4 2025
SOLID BIOSCIENCES- EXPANDS SOLID'S CLINICAL PIPELINE TO INCLUDE FIRST CARDIAC INDICATION WITH URGENT UNMET MEDICAL NEED
Source text: ID:nGNX77LwZJ
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.